Ipilimumab alone or in combination with nivolumab in patients with advanced melanoma who have progressed or relapsed on PD-1 blockade: clinical outcomes and translational biomarker analyses.
Claire F FriedmanChristine SpencerChristopher R CabanskiKatherine S PanageasDaniel K WellsAntoni RibasHussein A TawbiKaty TsaiMichael A PostowAlexander N ShoushtariPaul B ChapmanJoyson KarakunnelSamantha BucktroutPier GherardiniTravis J HollmannRichard O ChenMargaret CallahanTheresa LaValleeRamy IbrahimJedd WolchokPublished in: Journal for immunotherapy of cancer (2022)
NCT02731729.